Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03313505
Other study ID # 16-09
Secondary ID 2016-A00901-50
Status Completed
Phase
First received
Last updated
Start date May 14, 2018
Est. completion date July 22, 2021

Study information

Verified date July 2021
Source Centre Hospitalier Princesse Grace
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Brain injury is a frequent purpose for consultation in emergency services. Management of brain injury is time and resource consuming, combining clinical monitoring and imaging. The stage prior to the management of the victims of brain injury is stratification of the severity, potential or proven. Severe brain injury requires emergent brain CT-scan, ideally within one hour of the first medical contact. Patients requiring this strategy present with focused neurological deficit, Glasgow score <15 to 2 hours after the trauma, suspicion of open fracture of the skull or dish pan fracture, any signs of fracture of the skull base (hemotympanum, bilateral peri-orbital ecchymosis), otorrhea or rhinorrhea of cerebrospinal fluid, more than one episode of vomiting in adults, and posttraumatic convulsion. Patients benefiting from anticoagulant therapy are included in this category. Victims of brain injury that do not fall into this category are considered less critical. By definition, mild traumatic brain injury : - a trauma of the cephalic extremity : - whose Glasgow score (30 min after the trauma or during the consultation) is 13-15, - associated with one or more of the following: confusion; disorientation; loss of consciousness of 30 min or less; post-traumatic amnesia of less than 24 hours; other transient neurological abnormalities (focal signs, epileptic seizures, non-surgical intracranial lesion). Among these patients, some are considered at risk of developing intracerebral lesions. Nevertheless, it should be noted that the prevalence of hemorrhagic complications is radically different between patients with a Glasgow score of 13 and those with a score of 15. Thus, the recommendations suggest a brain scan without injection of contrast media within 4 to 8 hours for patients with the following characteristics : - a retrograde amnesia of more than 30 minutes, - a loss of consciousness or amnesia associated with: - either a risk mechanism (pedestrian overturned by a motor vehicle, ejection of a vehicle, falling by more than one meter), - or an age> 65 years, - or coagulation disorders, including the use of platelet aggregation therapy. Patients who fall outside this definition are considered low risk of complication and should not benefit of imaging. Data from the scientific literature show that an early brain CT-scan allows identification of post-traumatic lesions in this population. Nevertheless, organizational problems, including the availability of the imaging, radiation, and disruption of surveillance related to patient displacement, are limitations to this strategy. In contrast, the low cost-effectiveness of CT scan is often advocated in patients with mild traumatic brain injury. For example, in the Octopus study, 52 of 1316 patients who received CT scan after mild head trauma had an intracerebral lesion. Among these patients, 39 (3%) had intracerebral lesion related to trauma; for 13 (1%) patients, the link with the trauma was uncertain. In fact, the search of alternatives for a safer, more conservative, more efficient practice, one of the objectives of which is to limit the undue use of cerebral scanning. Thus, many teams have been interested in the use of biological variables to guide the decision to use imagery. Among candidate biomarkers, the S100B protein has been the subject of many evaluations which allow it to be used in current practice. Indeed, the increase of the S100B protein carried out within 3 hours following a mild head trauma makes it possible to identify the patients at risk of intracerebral lesion and to target the indications of imaging. The purpose of the registry is to describe the use, interpretation and performance of the S100B protein in its use at bedside in emergency medicine.


Recruitment information / eligibility

Status Completed
Enrollment 787
Est. completion date July 22, 2021
Est. primary completion date July 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult Patients - Victims of mild head trauma at risk of complication : o Adult patients with head trauma with: - retrograde amnesia of more than 30 minutes, or - loss of consciousness or amnesia of the facts associated with: - Either a risky mechanism (pedestrian overturned by a motor vehicle, ejection of a vehicle, drop of more than one meter), - either An age> 65 years, - Either clotting disorders, including platelet aggregation therapy. - either Glasgow Score to 15 - Admitted to the emergency department within three hours of the traumatic event. Exclusion Criteria: - Refusal to participate at the study - Patients with obstacle to 7 days follow up - Pregnant women - Patients not subject to an health insurance scheme in France or Monaco.

Study Design


Intervention

Biological:
S100B protein dosage
S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient
Other:
Brain CT scan
No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient

Locations

Country Name City State
France Centre Hospitalier Universitaire de Clermont-Ferrand Clermont-Ferrand
France AP-HP Centre Hospitalier Universitaire Henri-Mondor Créteil
France Hospices Civils de Lyon - Pôle Est Lyon
France AP-HM La Timone Marseille
France Centre Hospitalier de Metz-Thionville Metz
France Centre Hospitalier Universitaire de Nice, Hôpital Pasteur Nice
France Centre Hospitalier Universitaire de Nîmes - Hôpital Carémeau Nîmes
France AP-HP Nord Lariboisière Paris
France AP-HP Sud Pitié-Salpêtrière Paris
France Centre Hospitalier Universitaire de Poitiers Poitiers
France Hôpital Charles Nicolle Rouen
France CHU de Strasbourg Strasbourg
France HIA Sainte Anne Toulon
France Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan Toulouse
Monaco Centre Hospitalier Princesse Grace Monaco

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Princesse Grace

Countries where clinical trial is conducted

France,  Monaco, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the number of brain CT-scan saved in patients who have been tested for S100B protein Percentage (%) 53 weeks
Secondary Comparison of supported patients with S100B protein assay or without S100B protein assay Percentage (%) 53 weeks
Secondary Intensive treatment comparison of the patients included in the centers that carried out an "intensive implementation" of the use of the S100B protein and those included in the centers that provided the S100B protein Percentage (%) 53 weeks
Secondary Quantification and evaluation of deviations to the algorithm Percentage (%) 53 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04372797 - Standardized Instruments to Provide Diagnostic and Prognostic Information in Mild Traumatic Brain Injury (mTBI) N/A
Completed NCT01903525 - DHA For The Treatment of Pediatric Concussion Related to Sports Injury Phase 1
Completed NCT01847040 - Deployment Related Mild Traumatic Brain Injury (mTBI)
Completed NCT03678077 - Trends in Cohabitation Status, Academic Achievement and Socio-economic Indicators After Mild Traumatic Brain Injury
Recruiting NCT05682677 - Combined Neuromodulation and Cognitive Training for Post-mTBI Depression N/A
Terminated NCT03345550 - OPTIMA-TBI Pilot Study Phase 2
Completed NCT05095012 - RECOVER Clinical Pathway for Pediatric Concussion N/A
Recruiting NCT05886400 - The Effects of Environmental Distractions on SCAT6 Outcomes N/A
Recruiting NCT05262361 - Persistent Post-Concussion Symptoms With Convergence Insufficiency N/A
Active, not recruiting NCT03892291 - Objective Dual-task Turning Measures for Return-to-duty Assessments
Completed NCT03688984 - Treatment of Insomnia for Adolescents With Mild Traumatic Brain Injury N/A
Completed NCT02057081 - Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI N/A
Recruiting NCT06233851 - t-BIOMAP : Prospective Paediatric Cohort Study of Blood Biomarkers in mTBI
Completed NCT02844946 - One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology N/A
Completed NCT04641767 - BIOmarkers of TRAumatic Brain Injury Spain (BIOTRABIS)
Recruiting NCT06112093 - Repetitive Transcranial Magnetic Stimulation for Post-concussion Headaches N/A
Recruiting NCT03819608 - Neuromodulation and Neurorehabilitation for mTBI Plus PTSD N/A
Withdrawn NCT00580918 - Functional MRI Study of Attention in Normal Controls and Traumatic Brain Injured Patients
Completed NCT03319966 - Eyetracking and Neurovision Rehabilitation of Oculomotor Dysfunction in Mild Traumatic Brain Injury
Recruiting NCT03846830 - Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation N/A